| Identification | |
| Name: | Bosentan |
| Synonyms: | Actelion;Ro 47-0203;Ro 47-0203/039;Tracleer;p-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide;Benzenesulfonamide,4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-; |
| CAS: | 147536-97-8 |
| Molecular Formula: | C27H29N5O6S |
| Molecular Weight: | 551.61 |
| InChI: | InChI=1/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32) |
| Molecular Structure: |  |
| Properties | |
| Melting Point: | 195 ºC |
| Flash Point: | 402.8 ºC |
| Boiling Point: | 742.3 ºC at 760 mmHg |
| Density: | 1.326 g/cm3 |
| Refractive index: | 1.607 |
| Appearance: | Pale Yellow to Off-White Solid |
| Specification: |
Bosentan (CAS NO.147536-97-8) can be called Tracleer ; 4-Tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide ; N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide .It is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the European Union, the United States and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. |
| Flash Point: | 402.8 ºC |
| Usage: | A mixed endothelin receptor antagonist. Used as a vasodilator |
| Safety Data | |
 |
|
